-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 17, Pfizer and Ferring formally announced that the two parties have reached a cooperation agreement on Ferring’s authorization of Pfizer to exclusively be responsible for the commercial operation of degarelix acetate (brand name: Feimenger®), an innovative drug for the treatment of prostate cancer, in mainland China.
Degarelix Acetate for Injection is a drug developed by Ferring to treat prostate cancer.
As China's aging problem continues to deepen, the incidence of prostate cancer is on the rise
Note: The original text has been deleted
Reference
[1] Klotz et al (2008) The efficacy and safety of Degarelix: a 12month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
[2] Shi Xiaolei, Zhou Tie, Li Song, Sun Yinghao.
[3] Prostate Cancer Group, Professional Committee of Urinary and Male Reproductive System Tumors, Chinese Anti-Cancer Association.